BMS and Nektar Therapeutics announce oncology clinical collaboration

Bristol-Myers Squibb Company and Nektar Therapeutics have announced a new clinical collaboration to evaluate combining Bristol-Myers Squibb’s Opdivo with Nektar’s investigational medicine, NKTR-214, as a potential treatment regimen in five different tumour types and seven potential indications. Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression. Whilst NKTR-214 is an investigational immuno-stimulatory

Continue Reading

FDA Grants Bristol-Myers Squibb & AbbVie’s Elotuzumab Breakthrough Status

US regulatory body, the Food and Drug Administration (FDA), have granted breakthrough therapy status to Bristol-Myers Squibb and AbbVie’s elotuzumab to treat multiple myeloma (MM). The designation has been granted by the FDA for elotuzumab’s use with lenalidomide and dexamethasone in patients who have previously received one or more therapies to treat multiple myeloma. Elotuzumab

Continue Reading

Scottish Regulators Approve Forxiga for the NHS

Patients with diabetes in Scotland have gained routine access to AstraZeneca/ Bristol-Myers Squibb’s Forxiga on the UK National Health Service (NHS) after it was considered cost-effective by the Scottish Medicines Consortium (SMC). The SMC have dispensed guidance to healthcare professionals approving the use of the first-in-class drug Forxiga (BMS-512148) in adults with type 2 diabetes

Continue Reading

Bristol-Myers Squibb Completes Amylin Purchase

Bristol-Myers Squibb (B-MS) yesterday announced that they have completed their $5 billion purchase of Amylin and its diabetes franchise, meaning they can now progress onto a planned marketing alliance with drug giant AstraZeneca. The New York-based drug maker, who agreed to buy Amylin on the 1st July, confirmed that they have now successfully finalised their

Continue Reading

US FDA Approves Erbitux for KRAS Wild-Type Cancer

A new indication for Bristol-Myers Squibb (BMS) and Eli Lilly’s Erbitux, which is sold outside the USA by Merck KGaA, has been approved by US regulators. Meanwhile, the US Food and Drug Administration (FDA) have also cleared the first KRAS companion diagnostic test, the therascreen KRAS diagnostic kit which was developed by the Netherlands-based firm,

Continue Reading

Bristol-Myers Squibb Enter Partnership with Tibotec Pharmaceuticals

Bristol-Myers Squibb have entered into a clinical collaboration agreement with Tibotec Pharmaceuticals, one of the Janssen Pharmaceutical Companies, to assess the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb’s investigational NS5A replication complex inhibitor, combined with Tibotec Pharmaceuticals’ investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV). Within the agreement, the two

Continue Reading

EU Approval for Komboglyze and Onglyza

AstraZeneca and Bristol-Myers Squibb are celebrating after European regulators approved two of their diabetes drugs. AstraZeneca and Bristol-Myers Squibb Company announced today that the European Commission has granted marketing authorisation for Komboglyze,  which combines the DPP-4 inhibitor Onglyza (saxagliptin) with metformin in a once-a-day tablet. The combination is to be used as an adjunct to

Continue Reading

Aslan and Bristol-Myers Squibb Enter Cancer Partnership

Bristol-Myers Squibb has signed an innovative strategic partnership with Aslan Pharmaceuticals, headquartered in Singapore, which will see Aslan help develop one of the US major’s investigational cancer compounds. The drug in question, BMS-777607, is a small molecule inhibitor of the MET receptor tyrosine kinase for the treatment of solid tumours. Under the terms of the

Continue Reading

Disappointment as NICE Rejects Skin Cancer Drug

The conclusion by the UK’s National Institute for Health and Clinical Excellence (NICE) to reject Bristol-Myers Squibb’s new melanoma drug Yervoy has been greeted with disappointment by the company and patient groups. In a provisional draft guidance published earlier today, NICE decided against recommending payment by the UK’s National Health Service (NHS) of Yervoy (ipilimumab)

Continue Reading